Close

Dyax Corp (DYAX) Announces Positive Results from Phase 1b Trial of DX-2930 and Fast Track Designation

March 31, 2015 4:04 PM EDT Send to a Friend
Dyax Corp. (NASDAQ: DYAX) today announced positive safety, pharmacokinetic, biomarker, and efficacy results from the Phase 1b clinical study of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login